This study looks at how well a new treatment called Dato-DXd works, with or without another medication called osimertinib. It compares these treatments to standard chemotherapy for people with advanced non-small cell lung cancer who have not responded to previous osimertinib treatment. The main goal is to see how long patients can live without their cancer getting worse.
The trial's ID number is NCT06417814. This is a Phase 3 trial, which means it is looking at how well the treatment works and its safety. It is FDA-regulated and aims to include about 744 participants.
Who can join
Adults aged 18 and older can join. Both men and women are welcome. Participants must have a specific lung cancer type, have shown progression after prior osimertinib treatment, and meet other health criteria. The trial team will confirm who is eligible.
Condition
Metastatic Non-small Cell Lung Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
People in this trial will be placed into one of three groups by chance.
Group 1 receives Dato-DXd and osimertinib.
Group 2 receives only Dato-DXd.
Group 3 receives standard chemotherapy with platinum-based drugs.
Participants will receive treatment until their cancer progresses, they experience unacceptable side effects, or they meet other stopping criteria.
Where
This trial is enrolling at 34 locations. Recruiting sites are listed first.
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.